Company Profile

Attenuon LLC
Profile last edited on: 3/14/19      CAGE:       UEI:

Business Identifier: Anticancer drugs
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

11535 Sorrento Valley Road Suite 401
San Diego, CA 92121
   (858) 720-8797
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Attenuon, L.L.C. is a pharmaceutical company seeking to develop a new generation of cancer therapeutics: organized around developing cancer therapeutics to disrupt cellular signaling processes to tumor growth and metastatsis. instead of poisoning cells, these therapies are designed to selectively disrupt cellular signaling processes important to tumor growth and metastasis (the spreading of tumors). Based on this approach, Attenuon hopes to develop therapies that will be effective against many types of cancer, produce few side effects, be less prone to acquired drug resistance, be suitable for long-term use, and work well with existing therapies. The firm offered ATN-224 that disrupts signaling pathways involved in tumor growth, angiogenesis, and metastasis, including those mediated by multiple kinases, as well as NF-kappaB by inhibiting the enzyme superoxide dismutase; and ATN-161, a five-amino acid peptide derived from fibronectin. Coincident with its SBIR involvement. it was announced that the Japanese firm Kirin Brewery and its US subsidiary Gemini Science would work with Attenuon to develop fully human monoclonal antibody (MAb) candidates as cancer therapeutic and diagnostic agents.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 1 NIH $282,980
Project Title: A targeted peptide for PET imaging of cancer
2002 1 NIH $100,000
Project Title: Minimization of an anti-angiogenic protein

Key People / Management

  David E Shaw -- President

  Fernando Donate

Company News

There are no news available.